title: Rosacea: II. Therapy.
abstract: Despite an incomplete understanding of the pathogenesis of rosacea, therapeutic modalities continue to expand. The principal subtypes of rosacea include erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea. These phenotypic expressions are probably caused by divergent pathogenic factors and consequently respond to different therapeutic regimens. A subtype-directed approach to therapy is discussed in part II of this review. We provide an overview of the available topical, oral, laser, and light therapies in the context of these cutaneous subtypes, review the evidence that supports their use, and outline their therapeutic approach. Suggestions for future areas of study also are provided. Learning objective At the completion of this learning activity, participants should be familiar with the subtype-directed approach to therapy for rosacea including available topical, oral, laser, and light therapies.
authors.affiliation: Department of Dermatology, Boston University Medical Center, USA.
authors.forename: Michelle T
authors.initials: MT
authors.lastname: Pelle
authors.forename: Glen H
authors.initials: GH
authors.lastname: Crawford
authors.forename: William D
authors.initials: WD
authors.lastname: James
mesh_terms: D000890:Anti-Infective Agents / Q000191:economics / Q000627:therapeutic use; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use; D000075202:Contraindications; D003358:Cosmetics; D003365:Costs and Cost Analysis; D003879:Dermatologic Agents / Q000191:economics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010789:Phototherapy; D012393:Rosacea / Q000145:classification* / Q000209:etiology / Q000628:therapy*; D013473:Sunscreening Agents / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D003278:Contraceptives, Oral, Hormonal; D003358:Cosmetics; D003879:Dermatologic Agents; D013473:Sunscreening Agents